U.S. market Closed. Opens in 11 hours 50 minutes

ANIP | ANI Pharmaceuticals, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for ANIP we got that it has weak fundamentals where Valuation is considered to be slightly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is passable.

Valuation (41%)

Company Industry
P/E Ratio (TTM) 41.85 24.50
PEG Ratio (TTM) 1.60 2.33
P/S Ratio (TTM) 2.28 5.42
P/B Ratio (TTM) 2.48 5.06
P/FCF Ratio (TTM) 13.06 11.26
Price to 5YR AVG Earnings Ratio -43.96 5.17
Price to 5YR AVG FCF Ratio -2,461.93 23.99

Profitability (20%)

Company Industry
ROA (TTM) 2.93% 3.20%
ROE (TTM) 6.02% 31.38%
Net Profit Margin (TTM) 5.01% -10.10%
ROIC 5YR AVG -0.33% 10.85%

Growth (40%)

4QTR AVG 3YR AVG 5YR AVG
EPS 469.27% -203.26% -92.97%
Revenue 4.45% 2.36% 21.47%
Net Income 333.65% -206.54% -98.57%
Cash Flow 7.80% -58.92% -146.96%

Health (56%)

Company Industry
Current Ratio (TTM) 3.97 2.49
Quick Ratio (TTM) 3.07 1.83
D/E Ratio (TTM) 0.68 -0.01
Interest Coverage (TTM) 2.22 12.09
Piotroski F-Score 6 6
Altman Z-Score 2.82 4.74
LTL to 5YR AVG FCF -619.59 4.47
Shares Outstanding Growth 5YR AVG 9.34% 28.76%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙